Company: HSDTW
Filing Date: 2025-03-14
Form Type: PRE 14A
Source: 0001558370-25-003007
Chunk: 0

Company: Solana Co
Filing Date: 2025-03-14
Form: PRE 14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☒ |     | Preliminary Proxy Statement                                                     |
| ☐ |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ |     | Definitive Proxy Statement                                                      |
| ☐ |     | Definitive Additional Materials                                                 |
| ☐ |     | Soliciting Material under §240.14a-12                                           |

| HELIUS MEDICAL TECHNOLOGIES, INC.                                        |
| (Name of Registrant as Specified In Its Charter)                         |
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) |

Payment of Filing Fee (Check all boxes that apply):

| ☒ |     | No fee required.                                                                                     |
| ☐ |     | Fee paid previously with preliminary materials.                                                      |
| ☐ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

March 25, 2025 To our Stockholders: The 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Helius Medical Technologies, Inc. will be held on Monday, April 21, 2025, at 9:00 a.m. Eastern Time to conduct the following items of business:

| ● | Proposal 1: To elect six directors named in the accompanying proxy statement, each to serve for a one-year term until our 2026 annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal; |

| ● | Proposal 3: To approve, pursuant to Nasdaq listing rules, the issuance of up to 6,213,888 shares of our common stock upon the exercise of existing Series C and Series D warrants to purchase common stock issued to warrantholders in connection with the Warrant Exercise and Inducement Letters dated January 21, 2025; |

| ● | Proposal 4: To approve an amendment to our Certificate of Incorporation to effect a reverse split of